Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Tumor Biology
Published in: Tumor Biology 12/2015

01-12-2015 | Review

Harnessing the immunomodulatory effect of thermal and non-thermal ablative therapies for cancer treatment

Authors: Christopher Bastianpillai, Neophytos Petrides, Taimur Shah, Stephanie Guillaumier, Hashim U. Ahmed, Manit Arya

Published in: Tumor Biology | Issue 12/2015

Login to get access

Abstract

Minimally invasive interventional therapies are evolving rapidly and their use for the treatment of solid tumours is becoming more extensive. The in situ destruction of solid tumours by such therapies is thought to release antigens that can prime an antitumour immune response. In this review, we offer an overview of the current evidence for immune response activation associated with the utilisation of the main thermal and non-thermal ablation therapies currently in use today. This is followed by an assessment of the hypothesised mechanisms behind this immune response priming and by a discussion of potential methods of harnessing this specific response, which may subsequently be applicable in the treatment of cancer patients. References were identified through searches of PubMed/MEDLINE and Cochrane databases to identify peer-reviewed original articles, meta-analyses and reviews. Papers were searched from 1850 until October 2014. Articles were also identified through searches of the authors’ files. Only papers published in English were reviewed. Thermal and non-thermal therapies have the potential to stimulate antitumour immunity although the current body of evidence is based mostly on murine trials or small-scale phase 1 human trials. The evidence for this immune-modulatory response is currently the strongest in relation to cryotherapy and radiotherapy, although data is accumulating for related ablative treatments such as high-intensity focused ultrasound, radiofrequency ablation and irreversible electroporation. This effect may be greatly enhanced by combining these therapies with other immunostimulatory interventions. Evidence is emerging into the immunomodulatory effect associated with thermal and non-thermal ablative therapies used in cancer treatment in addition to the mechanism behind this effect and how it may be harnessed for therapeutic use. A potential exists for treatment approaches that combine ablation of the primary tumour with control and possible eradication of persistent, locally recurrent and metastatic disease. However, more work is needed into each of these modalities, initially in further animal studies and then subsequently in large-scale prospective human studies.
Literature
1.
Arnott J. Practical illustrations of the remedial efficacy of a very low or anaesthetic temperature—I. In cancer. The Lancet. 1850;56(1409):257–9.CrossRef
2.
Yantorno C, Soanes WA, Gonder MJ, Shulman S. Studies in cryo-immunology. I. The production of antibodies to urogenital tissue in consequence of freezing treatment. Immunology. 1967;12(4):395–410.PubMedPubMedCentral
3.
Soanes WA, Ablin RJ, Gonder MJ. Remission of metastatic lesions following cryosurgery in prostatic cancer: immunologic considerations. J Urol. 1970;104(1):154–9.PubMed
4.
Blackwood C, Cooper I. Response of experimental tumor systems to cryosurgery. Cryobiology. 1972;9(6):508–15.CrossRefPubMed
5.
Bagley DH, Faraci RP, Marrone JC, Beazley RM. Lymphocyte mediated cytotoxicity after cryosurgery of a murine sarcoma. J Surg Res. 1974;17(6):404–6.CrossRefPubMed
6.
Hoffmann NE, Coad JE, Huot CS, Swanlund DJ, Bischof JC. Investigation of the mechanism and the effect of cryoimmunology in the Copenhagen rat. Cryobiology. 2001;42(1):59–68.CrossRefPubMed
7.
Yamashita T, Hayakawa K, Hosokawa M, Kodama T, Inoue N, Tomita K, et al. Enhanced tumor metastases in rats following cryosurgery of primary tumor. Gann. 1982;73(2):222–8.PubMed
8.
Wu F, Zhou L, Chen WR. Host antitumour immune responses to HIFU ablation. International Journal of Hyperthermia. 2007;23(2):165–71.CrossRefPubMed
9.
Yang R, Reilly CR, Rescorla FJ, Sanghvi NT, Fry FJ, Franklin Jr TD, et al. Effects of high-intensity focused ultrasound in the treatment of experimental neuroblastoma. J Pediatr Surg. 1992;27(2):246–51.CrossRefPubMed
10.
Rosberger DF, Coleman DJ, Silverman R, Woods S, Rondeau M, Cunningham-Rundles S. Immunomodulation in choroidal melanoma: reversal of inverted CD4/CD8 ratios following treatment with ultrasonic hyperthermia. Biotechnol Ther. 1994;5(1–2):59–68.PubMed
11.
Wu F, Wang Z, Lu P, Xu Z, Chen W, Zhu H, et al. Activated anti-tumor immunity in cancer patients after high intensity focused ultrasound ablation. Ultrasound Med Biol. 2004;30(9):1217–22.CrossRefPubMed
12.
Zhou Q, Zhu X, Zhang J, Xu Z, Lu P, Wu F. Changes in circulating immunosuppressive cytokine levels of cancer patients after high intensity focused ultrasound treatment. Ultrasound Med Biol. 2008;34(1):81–7.CrossRefPubMed
13.
Zhang Y, Deng J, Feng J, Wu F. Enhancement of antitumor vaccine in ablated hepatocellular carcinoma by high-intensity focused ultrasound. World J Gastroenterol. 2010;16(28):3584–91.CrossRefPubMedPubMedCentral
14.
Hu Z, Yang XY, Liu Y, Morse MA, Lyerly HK, Clay TM, et al. Release of endogenous danger signals from HIFU-treated tumor cells and their stimulatory effects on APCs. Biochem Biophys Res Commun. 2005;335(1):124–31.CrossRefPubMedPubMedCentral
15.
Hu Z, Yang XY, Liu Y, Sankin GN, Pua EC, Morse MA, et al. Investigation of HIFU-induced anti-tumor immunity in a murine tumor model. J Transl Med. 2007;5(1):34.CrossRefPubMedPubMedCentral
16.
Van Leenders GJ, Beerlage HP, Ruijter ET, de la Rosette JJ, van de Kaa CA. Histopathological changes associated with high intensity focused ultrasound (HIFU) treatment for localised adenocarcinoma of the prostate. J Clin Pathol. 2000;53(5):391–4.CrossRefPubMedPubMedCentral
17.
Kramer G, Steiner GE, Gröbl M, Hrachowitz K, Reithmayr F, Paucz L, et al. Response to sublethal heat treatment of prostatic tumor cells and of prostatic tumor infiltrating T‐cells. Prostate. 2004;58(2):109–20.CrossRefPubMed
18.
Pockley AG. Heat shock proteins as regulators of the immune response. The Lancet. 2003;362(9382):469–76.CrossRef
19.
Davalos RV, Mir L, Rubinsky B. Tissue ablation with irreversible electroporation. Ann Biomed Eng. 2005;33(2):223–31.CrossRefPubMed
20.
André F, Connault E, Opolon P, Davalos R, Mir L. A study of the immunological response to tumor ablation with irreversible electroporation. Technol Cancer Res Treat. 2007;6(4):301–6.CrossRefPubMed
21.
Rubinsky B. Irreversible electroporation: implications for prostate ablation. Technol Cancer Res Treat 2007;6(4).
22.
23.
Neal II RE, Rossmeisl Jr JH, Robertson JL, Arena CB, Davis EM, Singh RN, et al. Improved local and systemic anti-tumor efficacy for irreversible electroporation in immunocompetent versus immunodeficient mice. PloS One. 2013;8(5):e64559.CrossRefPubMedPubMedCentral
24.
Wissniowski TT, Hansler J, Neureiter D, Frieser M, Schaber S, Esslinger B, et al. Activation of tumor-specific T lymphocytes by radio-frequency ablation of the VX2 hepatoma in rabbits. Cancer Res. 2003;63(19):6496–500.PubMed
25.
den Brok MH, Sutmuller RP, van der Voort R, Bennink EJ, Figdor CG, Ruers TJ, et al. In situ tumor ablation creates an antigen source for the generation of antitumor immunity. Cancer Res. 2004;64(11):4024–9.CrossRef
26.
Zerbini A, Pilli M, Penna A, Pelosi G, Schianchi C, Molinari A, et al. Radiofrequency thermal ablation of hepatocellular carcinoma liver nodules can activate and enhance tumor-specific T-cell responses. Cancer Res. 2006;66(2):1139–46.CrossRefPubMed
27.
GERDSCHUELLER JK, SEDIVY R, BERGMEISTER H, STIFT A, FRIED J, GNANT M, et al. Expression of heat shock proteins in human hepatocellular carcinoma after radiofrequency ablation in an animal model. Oncol Rep. 2004;12:495–9.
28.
Schueller G, Kettenbach J, Sedivy R, Stift A, Friedl J, Gnant M, et al. Heat shock protein expression induced by percutaneous radiofrequency ablation of hepatocellular carcinoma in vivo. Int J Oncol. 2004;24(3):609–13.PubMed
29.
Dromi SA, Walsh MP, Herby S, Traughber B, Xie J, Sharma KV, et al. Radiofrequency ablation induces antigen-presenting cell infiltration and amplification of weak tumor-induced immunity 1. Radiology. 2009;251(1):58–66.CrossRefPubMedPubMedCentral
30.
Napoletano C. RFA strongly modulates the immune system and anti-tumor immune responses in metastatic liver patients. Int J Oncol. 2008;32(2):481–90.PubMed
31.
Seki T, Wakabayashi M, Nakagawa T, Itho T, Shiro T, Kunieda K, et al. Ultrasonically guided percutaneous microwave coagulation therapy for small hepatocellular carcinoma. Cancer. 1994;74(3):817–25.CrossRefPubMed
32.
Nakayama J, Kokuba H, Kobayashi J, Yoshida Y, Hori Y. Experimental approaches for the treatment of murine B16 melanomas of various sizes. II: injection of ethanol with combinations of β-interferon and microwaval hyperthermia for B16 melanomas with a size of greater than 10 mm in diameter. J Dermatol Sci. 1997;15(2):82–8.CrossRefPubMed
33.
Dong B, Zhang J, Liang P, Yu X, Su L, Yu D, et al. Influencing factors of local immunocyte infiltration in hepatocellular carcinoma tissues pre- and post-percutaneous microwave coagulation therapy. Zhonghua Yi Xue Za Zhi. 2002;82(6):393–7.PubMed
34.
Zhang J, Dong B, Liang P, Yu X, Su L, Yu D, et al. Significance of changes in local immunity in patients with hepatocellular carcinoma after percutaneous microwave coagulation therapy. Chin Med J (Engl). 2002;115(9):1367–71.
35.
Szmigielski S, Sobczynski J, Sokolska G, Stawarz B, Zielinski H, Petrovich Z. Effects of local prostatic hyperthermia on human NK and T cell function. International Journal of Hyperthermia. 1991;7(6):869–80.CrossRefPubMed
36.
Dong BW, Zhang J, Liang P, Yu X, Su L, Yu D, et al. Sequential pathological and immunologic analysis of percutaneous microwave coagulation therapy of hepatocellular carcinoma. International Journal of Hyperthermia. 2003;19(2):119–33.CrossRefPubMed
37.
Evans S, Matthews W, Perry R, Fraker D, Norton J, Pass HI. Effect of photodynamic therapy on tumor necrosis factor production by murine macrophages. J Natl Cancer Inst. 1990;82(1):34–9.CrossRefPubMed
38.
Steubing RW, Yeturu S, Tuccillo A, Sun C, Berns M. Activation of macrophages by Photofrin II during photodynamic therapy. Journal of Photochemistry and Photobiology B: Biology. 1991;10(1):133–45.CrossRef
39.
Chen WR, Zhu W, Dynlacht JR, Liu H, Nordquist RE. Long‐term tumor resistance induced by laser photo‐immunotherapy. International Journal of Cancer. 1999;81(5):808–12.CrossRefPubMed
40.
Korbelik M, Krosl G, Krosl J, Dougherty GJ. The role of host lymphoid populations in the response of mouse EMT6 tumor to photodynamic therapy. Cancer Res. 1996;56(24):5647–52.PubMed
41.
Oleinick NL, Evans HH. The photobiology of photodynamic therapy: cellular targets and mechanisms. Radiat Res. 1998;150(5s):S146–56.CrossRefPubMed
42.
Korbelik M, Sun J, Cecic I. Photodynamic therapy-induced cell surface expression and release of heat shock proteins: relevance for tumor response. Cancer Res. 2005;65(3):1018–26.PubMed
43.
Cecic I et al. Mediators of peripheral blood neutrophilia induced by photodynamic therapy of solid tumors. Cancer Lett. 2002;183(1):43–51.CrossRefPubMed
44.
Krosl G, Korbelik M, Krosl J, Dougherty GJ. Potentiation of photodynamic therapy-elicited antitumor response by localized treatment with granulocyte-macrophage colony-stimulating factor. Cancer Res. 1996;56(14):3281–6.PubMed
45.
Golab J, Wilczynski G, Zagozdzon R, Stoklosa T, Dabrowska A, Rybczynska J, et al. Potentiation of the anti-tumour effects of Photofrin-based photodynamic therapy by localized treatment with G-CSF. Br J Cancer. 2000;82(8):1485–91.CrossRefPubMedPubMedCentral
46.
Zhang H, Sun M, Guha D, Liu L, Alfieri A, Guha C. Generation of tumor specific immune response with therapeutic focused ultrasound. Cancer Res. 2010;70(8 Supplement):5630.CrossRef
47.
Immune system modulation with LOFU and HIFU treatment of prostate cancer. 10th International Symposium on Therapeutic Ultrasound (ISTU 2010): AIP Publishing; 2011
48.
Slone HB, Peters LJ, Milas L. Effect of host immune capability on radiocurability and subsequent transplantability of a murine fibrosarcoma. J Natl Cancer Inst. 1979;63(5):1229–35.
49.
Apetoh L, Ghiringhelli F, Zitvogel L. Calreticulin dictates the immunogenicity of anti-cancer chemotherapy and radiotherapy. Med Sci (Paris). 2007;23(3):257–8.CrossRef
50.
51.
Apetoh L, Ghiringhelli F, Tesniere A, Obeid M, Ortiz C, Criollo A, et al. Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy. Nat Med. 2007;13(9):1050–9.CrossRefPubMed
52.
Matsumura S, Wang B, Kawashima N, Braunstein S, Badura M, Cameron TO, et al. Radiation-induced CXCL16 release by breast cancer cells attracts effector T cells. J Immunol. 2008;181(5):3099–107.CrossRefPubMedPubMedCentral
53.
Lugade AA, Sorensen EW, Gerber SA, Moran JP, Frelinger JG, Lord EM. Radiation-induced IFN-gamma production within the tumor microenvironment influences antitumor immunity. J Immunol. 2008;180(5):3132–9.CrossRefPubMed
54.
55.
Ohba K, Omagari K, Nakamura T, Ikuno N, Saeki S, Matsuo I, et al. Abscopal regression of hepatocellular carcinoma after radiotherapy for bone metastasis. Gut. 1998;43(4):575–7.CrossRefPubMedPubMedCentral
56.
Antoniades J, Brady LW, Lightfoot DA. Lymphangiographic demonstration of the abscopal effect in patients with malignant lymphomas. International Journal of Radiation Oncology* Biology* Physics. 1977;2(1):141–7.CrossRef
57.
Rees G, Ross C. Abscopal regression following radiotherapy for adenocarcinoma. Br J Radiol. 1983;56(661):63–6.CrossRefPubMed
58.
Ehlers G, Fridman M. Abscopal effect of radiation in papillary adenocarcinoma. Br J Radiol. 1973;46(543):220–2.CrossRefPubMed
59.
Von Essen C. Radiation enhancement of metastasis: a review. Clin Exp Metastasis. 1991;9(2):77–104.CrossRef
60.
Camphausen K, Moses MA, Menard C, Sproull M, Beecken WD, Folkman J, et al. Radiation abscopal antitumor effect is mediated through p53. Cancer Res. 2003;63(8):1990–3.PubMed
61.
62.
Budhu S, Loike JD, Pandolfi A, Han S, Catalano G, Constantinescu A, et al. CD8+ T cell concentration determines their efficiency in killing cognate antigen-expressing syngeneic mammalian cells in vitro and in mouse tissues. J Exp Med. 2010;207(1):223–35.CrossRefPubMedPubMedCentral
63.
Barcellos-Hoff MH, Derynck R, Tsang ML, Weatherbee JA. Transforming growth factor-beta activation in irradiated murine mammary gland. J Clin Invest. 1994;93(2):892–9.CrossRefPubMedPubMedCentral
64.
Kachikwu EL, Iwamoto KS, Liao Y, DeMarco JJ, Agazaryan N, Economou JS, et al. Radiation enhances regulatory T cell representation. International Journal of Radiation Oncology* Biology* Physics. 2011;81(4):1128–35.CrossRef
65.
66.
Sabel MS, Su G, Griffith KA, Chang AE. Rate of freeze alters the immunologic response after cryoablation of breast cancer. Annals of Surgical Oncology. 2010;17(4):1187–93.CrossRefPubMed
67.
Sabel MS. Cryo-immunology: a review of the literature and proposed mechanisms for stimulatory versus suppressive immune responses. Cryobiology. 2009;58(1):1–11.CrossRefPubMed
68.
69.
Whiteside TL. The tumor microenviroment and its role in promoting tumour growth. Oncogene. 2010;27(45):1187–93.
70.
Levy MY, Sidana A, Chowdhury WH, Solomon SB, Drake CG, Rodriguez R, et al. Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation. J Pharmacol Exp Ther. 2009;330(2):596–601.CrossRefPubMedPubMedCentral
71.
den Brok M, Sutmuller RP, Nierkens S, Bennink EJ, Frielink C, Toonen LW, et al. Efficient loading of dendritic cells following cryo and radiofrequency ablation in combination with immune modulation induces anti-tumour immunity. Br J Cancer. 2006;95(7):896–905.CrossRef
72.
Thakur A, Littrup P, Paul EN, Adam B, Heilbrun LK, Lum LG. Induction of specific cellular and humoral responses against renal cell carcinoma after combination therapy with cryoablation and granulocyte-macrophage colony stimulating factor: a pilot study. J Immunother. 2011;34(5):457–67.CrossRefPubMedPubMedCentral
73.
74.
Niu L, Mu F, Zhang C, Li Y, Liu W, Jiang F, et al. Cryotherapy protocols for metastatic breast cancer after failure of radical surgery. Cryobiology. 2013;67(1):17–22.CrossRefPubMed
75.
Liang Z, Fei Y, Lizhi N, Jianying Z, Zhikai Z, Jibing C, et al. Percutaneous cryotherapy for metastatic bladder cancer: experience with 23 patients. Cryobiology. 2014;68(1):79–83.CrossRefPubMed
76.
Waitz R, Solomon SB, Petre EN, et al. Potent induction of tumour immunity by combining tumour cryoablation with anti-CTLA-4 therapy. Cancer Res. 2012;72(2):430–9.CrossRefPubMed
77.
Imai Y, Ishida M, Tanaka T et al. Involvement of PD-L1 on tumour cells in the escape from host immune system and tumour immunotherapy by PD-L1 blockade. Proc. Natl. Acad Sci. USA99(19), 12293–12297 (2002)
78.
Nikitina EY, Gabrilovich DI. Combination of γ‐irradiation and dendritic cell administration induces a potent antitumor response in tumor‐bearing mice: approach to treatment of advanced stage cancer. International Journal of Cancer. 2001;94(6):825–33.CrossRefPubMed
79.
Dewan MZ, Galloway AE, Kawashima N, Dewyngaert JK, Babb JS, Formenti SC, et al. Fractionated but not single-dose radiotherapy induces an immune-mediated abscopal effect when combined with anti-CTLA-4 antibody. Clin Cancer Res. 2009;15(17):5379–88.CrossRefPubMedPubMedCentral
80.
Harris TJ, Hipkiss EL, Borzillary S, Wada S, Grosso JF, Yen H, et al. Radiotherapy augments the immune response to prostate cancer in a time‐dependent manner. Prostate. 2008;68(12):1319–29.CrossRefPubMedPubMedCentral
81.
Chi K, Liu S, Li C, Kuo H, Wang Y, Chao Y, et al. Combination of conformal radiotherapy and intratumoral injection of adoptive dendritic cell immunotherapy in refractory hepatoma. Journal of Immunotherapy. 2005;28(2):129–35.CrossRefPubMed
82.
Gulley JL, Arlen PM, Bastian A, Morin S, Marte J, Beetham P, et al. Combining a recombinant cancer vaccine with standard definitive radiotherapy in patients with localized prostate cancer. Clin Cancer Res. 2005;11(9):3353–62.CrossRefPubMed
83.
Gameiro SR, Higgins JP, Dreher MR, Woods DL, Reddy G, Wood BJ, et al. Combination therapy with local radiofrequency ablation and systemic vaccine enhances antitumor immunity and mediates local and distal tumor regression. PLoS One. 2013;8(7):e70417.CrossRefPubMedPubMedCentral
Metadata
Title
Harnessing the immunomodulatory effect of thermal and non-thermal ablative therapies for cancer treatment
Authors
Christopher Bastianpillai
Neophytos Petrides
Taimur Shah
Stephanie Guillaumier
Hashim U. Ahmed
Manit Arya
Publication date
01-12-2015
Publisher
Springer Netherlands
Published in
Tumor Biology / Issue 12/2015
Print ISSN: 1010-4283
Electronic ISSN: 1423-0380
DOI
https://doi.org/10.1007/s13277-015-4126-3

Other articles of this Issue 12/2015

Tumor Biology 12/2015 Go to the issue

Research Article

Quercetin 3-O-glucoside suppresses epidermal growth factor–induced migration by inhibiting EGFR signaling in pancreatic cancer cells

Research Article

Alpha 7-nicotinic acetylcholine receptor mediates the sensitivity of gastric cancer cells to 5-fluorouracil

Research Article

ABCG2 is a potential marker of tumor-initiating cells in breast cancer

Research Article

High expression of CD39/ENTPD1 in malignant epithelial cells of human rectal adenocarcinoma

Research Article

High-mobility group nucleosome-binding protein 1 is a novel clinical biomarker in non-small cell lung cancer

Research Article

Elevated miR-483-3p expression is an early event and indicates poor prognosis in pancreatic ductal adenocarcinoma
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits